This study not only expands the application of aptamer SERS biomarker technology, but also provides new experimental data and understanding for the study of the dynamic process of immune ...

The aptamer directs the drug to the desired tissue or cell type, reducing off-target effects and enhancing therapeutic efficacy. Aptamers can be labeled with fluorescent dyes or radionuclides for ...

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) ...

In this roundtable discussion, an expert panel will discuss how the latest applications of aptamer technology are enabling innovation across the life sciences by replacing antibodies. Experts from the ...

Japanese drugmaker Astellas Pharma says it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor ...

York-based biotech firm, the Aptamer Group, has reported “Revenue growth and significant commercial and technical progress” in its ...

Aptamer Group plc (AIM: APTA), the developer of novel Optimer ... presenting an opportunity for Optimer binders to address targets and applications where traditional antibodies fall short. Following ...